| Porteus Interview on Graphite Bio CRISPR treatment of Sickle Cell Disease The outstanding results from the first CRISPR gene editing therapy for haemoglobinopathies by Vertex Pharmaceuticals and CRISPR Therapeutics has only just landed when news of a second more direct approach arrived.
With a new IND in hand, Graphite Bio plans to begin clinical trials for a CRISPR treatment that will restore normal haemoglobin expression in Sickle Cell Disease patients. The news raises hope for millions of people worldwide, and we talk to gene editing pioneer, Dr. Matthew Porteus, Stanford University. He is both a co-founder of Graphite Bio and a scientific founder of CRISPR Therapeutics: There Are Now Two Pushes to Treat Sickle Cell Disease With CRISPR. | |
